Keywords:
Inflammation, Biopsy, CT, Thorax, Lung
Authors:
M. Benegas Urteaga1, M. Sanchez1, I. Vollmer2, F. Hernandez 2, C. Lucena 2, J. Ramirez1, J. Sellares1; 1Barcelona/ES, 2Barcelona /ES
DOI:
10.26044/esti2019/P-0112
Background
The interstitial lung diseases (ILDs) are a complex group of conditions that present with nonspecific symptoms.
One of the more common and the most fatal of the ILDs is idiopathic pulmonary fibrosis (IPF).
IPF is a specific form of chronic,
progressive,
fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults.
It is defined by the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP).
To achieve an accurate diagnosis of ILD,
the multidisciplinary review is often necessary.
The first evidence-based guidelines for the diagnosis and treatment of IPF were published in 2011,
with the treatment recommendations updated in 2015.
In 2018 two guidance documents for the diagnosis of IPF have been published by international multidisciplinary experts representing major respiratory and radiological societies: the Fleischner Society White Paper Consensus Statement and the American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Society (ALAT) guideline on the diagnosis of IPF.
Diagnostic criteria for IPF have been updated and recommendations for diagnostic interventions have been provided.
The ATS/ERS/JRS/ALAT guidelines and Fleischner Society statement reach similar conclusions and recommendations,
with only small differences.
The multidisciplinary approach to IPF diagnosis is essential in both guidelines.
We review the major recent changes in the diagnosis approach of IPF according to 2018 guidelines in a case-based multidisciplinary approach.